105 patents currently held
12 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Aug 2030. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
18
Ending by 2030
Aug 2030
Next term end
47
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Mar 2033 · High confidence
Also notable
Ends Sep 2031 · High confidence
Also notable
Ends Aug 2030 · High confidence
Also notable
Ends May 2033 · High confidence
Also notable
Ends no later than Oct 2032 · Medium confidence
Also notable
Ends Jun 2037 · High confidence
Also notable
Ends Aug 2031 · High confidence
Also notable
Ends Apr 2037 · High confidence
Indazole Inhibitors of the WNT Signal Pathway and Therapeutic Uses Thereof
US 9,994,563
Cited by 52 later US patents, top 5% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2033.
1H-Pyrazolo[3,4-b]pyridines and Therapeutic Uses Thereof
US 8,450,340
The most cited patent in this portfolio, cited by 167 later US patents, top 5% of utility patents granted in 2013 in our data. Protection runs to 2031.
Indazole Inhibitors of the WNT Signal Pathway and Therapeutic Uses Thereof
US 9,090,613
Cited by 97 later US patents, top 5% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2030. A terminal disclaimer caps this term to an earlier patent's.
1H-Pyrazolo[3,4-b]pyridines and Therapeutic Uses Thereof
US 9,233,104
Cited by 83 later US patents, top 5% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2033.
INDAZOLE-3-Carboxamides AND THEIR USE AS WNT/Beta-CATENIN SIGNALING PATHWAY INHIBITORS
US 9,221,793
Cited by 149 later US patents, top 5% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2032. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Process for Preparing N-(5-(3-(7-(3-fluorophenyl)-3H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide
US 10,072,004
Cited by 47 later US patents, top 5% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2037.
B- AND y -DIKETONES AND y -HYDROXYKETONES AS WNT/ B -CATENIN SIGNALING PATHWAY ACTIVATORS
US 9,303,010
Cited by 24 later US patents, top 25% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2031. A terminal disclaimer caps this term to an earlier patent's.
ISOQUINOLIN-3-YL Carboxamides and Preparation and Use Thereof
US 10,508,099
Cited by 17 later US patents, top 25% of utility patents granted in 2019 in our data. Protection runs to 2037. A terminal disclaimer caps this term to an earlier patent's.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 7 fees due Dec 6 to 30, 2026 · next Dec 6
- 3 fees due Jan 9 to 28, 2027 · next Jan 9
- 3 fees due Feb 1 to 27, 2027 · next Feb 1
- 2 fees due Mar 10 to 17, 2027 · next Mar 10
- 3 fees due Apr 8 to 29, 2027 · next Apr 8
- 3 fees due May 5 to 21, 2027 · next May 5
- 5 fees due Jun 1 to 30, 2027 · next Jun 1
- 4 fees due Jul 7 to 28, 2027 · next Jul 7
- 1 fee due Aug 11, 2027The maintenance fee for ISOQUINOLIN-3-YL Carboxamides and Preparation and Use Thereof (US 10,556,885) comes due Aug 11, 2027. Unpaid by Feb 11, 2028, it lapses early.
- 3 fees due Sep 24 to 30, 2027 · next Sep 24
- 2 fees due Oct 5 to 28, 2027 · next Oct 5
- 2 fees due Nov 19, 2027
Recent changes
- 1 of the patents on this record was granted since Aug 23, 2026
- 5 terms have ended since Aug 23, 2026
- Oct 23 US 10,105,370 1H-Pyrazolo[3,4-b]pyridines and Therapeutic Uses Thereof · lapsed on the fee record
- Sep 30 US 8,846,714 1H-Pyrazolo[3,4-b]pyridines and Therapeutic Uses Thereof · lapsed on the fee record
- Sep 25 US 10,081,631 2-(1H-Indazol-3-yl)-1H-imidazo[4,5-c]pyridine and Therapeutic Uses Thereof · lapsed on the fee record
- Sep 11 US 10,071,086 1H-Pyrazolo[3,4-b]pyridines and Therapeutic Uses Thereof · lapsed on the fee record
- Aug 26 US 8,815,897 1H-Pyrazolo[3,4-b]pyridines and Therapeutic Uses Thereof · lapsed on the fee record
What they patent
The largest of its 47 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,252,812 | Indazole Inhibitors of the WNT Signal Pathway and Therapeutic Uses Thereof In force · High confidence | In force | High confidence | |
| US 8,664,241 | Indazole Inhibitors of the WNT Signal Pathway and Therapeutic Uses Thereof In force · High confidence | In force | High confidence | |
| US 8,673,936 | Indazole Inhibitors of the WNT Signal Pathway and Therapeutic Uses Thereof In force · High confidence | In force | High confidence | |
| US 8,703,794 | Indazole Inhibitors of the WNT Signal Pathway and Therapeutic Uses Thereof In force · High confidence | In force | High confidence | |
| US 9,090,613 | Indazole Inhibitors of the WNT Signal Pathway and Therapeutic Uses Thereof In force · High confidence | In force | High confidence | |
| US 9,199,991 | Indazole Inhibitors of the WNT Signal Pathway and Therapeutic Uses Thereof In force · High confidence | In force | High confidence | |
| US 9,381,192 | Indazole Inhibitors of the WNT Signal Pathway and Therapeutic Uses Thereof In force · High confidence | In force | High confidence | |
| US 9,763,927 | Indazole Inhibitors of the WNT Signal Pathway and Therapeutic Uses Thereof In force · High confidence | In force | High confidence | |
| US 10,407,425 | Indazole Inhibitors of the WNT Signal Pathway and Therapeutic Uses Thereof In force · High confidence | In force | High confidence | |
| US 8,822,478 | Indazole Inhibitors of the WNT Signal Pathway and Therapeutic Uses Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 105: 12 patents in force now held by others · 18 patents ended · 10 applications pending · 6 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.